ABBV — AbbVie Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Dividends
Measured signals that fired on ABBV
| date | signal | measured base rate |
|---|---|---|
| 2026-08-19 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-08-19 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-07-31 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-27 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-06-26 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-06-05 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-14 | Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER | Open-market sale | 32.7K | 250.00 | 8.2M |
| 2026-08-14 | Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER | Option exercise | 32.7K | 79.02 | 2.6M |
| 2026-05-08 | WADDELL FREDERICK H Director | Grant or award | 1.1K | 0.00 | 0 |
| 2026-05-08 | FALK THOMAS J Director | Grant or award | 1.1K | 0.00 | 0 |
| 2026-05-08 | Roberts Rebecca B Director | Grant or award | 1.1K | 0.00 | 0 |
| 2026-05-08 | FREYMAN THOMAS C Director | Grant or award | 1.1K | 0.00 | 0 |
| 2026-05-08 | RAPP EDWARD J Director | Grant or award | 1.1K | 0.00 | 0 |
| 2026-05-08 | Hart Brett J Director | Grant or award | 1.1K | 0.00 | 0 |
| 2026-05-08 | BURNSIDE WILLIAM H.L. Director | Grant or award | 1.1K | 0.00 | 0 |
| 2026-05-08 | AUSTIN ROXANNE S Director | Grant or award | 1.1K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 32.8B | 150.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 25.0B | 114.9M |
| STATE STREET CORP | 17.7B | 81.2M |
| JPMORGAN CHASE & CO | 12.1B | 56.7M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 10.8B | 49.5M |
| GEODE CAPITAL MANAGEMENT, LLC | 10.1B | 46.7M |
| MORGAN STANLEY | 8.3B | 38.0M |
| Capital Research Global Investors | 6.8B | 31.3M |
| BANK OF AMERICA CORP /DE/ | 5.2B | 23.9M |
| FMR LLC | 4.7B | 21.8M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- AbbVie To Present New Data From Its ABBV-1480 PD-1/VEGF Bispecific Antibody In Frontline Non-Small Cell Lung Cancer At 2026 World Conference On Lung Cancer · 2026-08-21 · benzinga
- Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303 · 2026-08-20 · benzinga
- Abbvie Inc. (ABBV) filed form 8-K · 2026-08-18 · SEC EDGAR
- 10 Health Care Stocks Whale Activity In Today’s Session · 2026-08-18 · benzinga
- Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300 · 2026-08-17 · benzinga
- Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target · 2026-08-13 · benzinga
Others in Healthcare
Ask the AI about ABBV
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →